Ignite Creation Date:
2024-05-06 @ 1:58 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01945021
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2013-09-05
Brief Title:
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive ALK Negative Advanced NSCLC
Sponsor:
Organization:
Pfizer